Overcoming clinical barriers to cell transplantation technologies
Our panel of experts discuss how cell transportation technologies have the potential to emerge as an effective treatment option for a wide range of diseases.
Cell transplantation technologies have shown great potential in treating various diseases, including neurological conditions, cardiovascular diseases and cancer. However, despite the promising results, these technologies face numerous barriers that prevent widespread adoption.
In this webinar we explore how the scientific and medical communities, as well as regulatory bodies, overcome issues with quality, cost and standardization, to improve the availability and quality of transplanted cells, reducing the cost of transplantation procedures, and develop methods to overcome the immune response.
Introducing our panellists:
Professor Clare Parish, Florey Institute of Neuroscience and Mental Health, University of Melbourne
Professor Clare Parish is head of the Florey's Neuro regeneration theme.
Professor Parish heads the Stem Cells and Neural Development. Her lab has a broad research interest relating to repairing the injured brain. Her team places a strong emphasis on understanding neural development, with the idea that recapitulating many of these early events will influence regeneration. Consequently, major research themes within her group include; understanding neural development; directed differentiation of human pluripotent stem cells; molecular mechanisms underlying axonal plasticity and improving cell-replacement therapy for brain repair. She has a particular interest in stem cell-based therapies for the treatment of Parkinson’s disease, Stroke and Huntington’s disease.
Professor Megan Munsie, Melbourne Medical School and Murdoch Children’s Research Institute
Professor Megan Munsie PhD is a developmental biologist and interdisciplinary scholar who leads research programs into ethical, legal and social implications of stem cell research at Murdoch Children’s Research Institute, University of Melbourne and reNEW, the Novo Nordisk Foundation Center for Stem Cell Medicine. Findings from her research have influenced policy reforms at a national and international level, and informed the design and delivery of educational resources for patients, healthcare professionals and the general public. She is internationally recognised for her contribution to public outreach and policy advocacy, and is the President of the Australasian Society for Stem Cell Research.
Dr Richard Boyd, Chief Scientific Officer, Cartherics Pty Ltd
Professor of Immunology at Monash University, Dr Richard Boyd is an expert in the nature and function of the thymus microenvironment for forming T cells from blood stem cells. He has pioneered clinical trials to boost the T cell-based immune system in cancer patients through rejuvenation of the thymus.
Professor David Nisbet, Director, Graeme Clark Institute for Biomedical Engineering, University of Melbourne (Chair)
David Nisbet is a Professor of Translational Biomedical Engineering at the University of Melbourne. He is the Director of the Graeme Clark Institute and the Head of the Laboratory of Advanced Biomaterials. Prof Nisbet is passionate about developing biomaterials, and seeing the biomaterials developed translated into the clinic. His research group consists of a team of engineers, chemists, and biologists, all working together to create novel materials to help combat disease and injury.
Presented by the MedTech Platform, Faculty of Engineering and IT